Botanix Pharmaceuticals, a listed developer of treatments for skin infections and diseases, was pitching investors for a $40 million equity raise on Monday morning.
Botanix’s lead product is used to treat excessive sweating. Dion Georgopoulos
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
